Literature DB >> 30926552

Morphologic Changes After Denosumab Therapy in Patients with Giant Cell Tumor of the Spine: Report of Four Cases and a Review of the Literature.

Noritaka Yonezawa1, Hideki Murakami2, Satoru Demura1, Satoshi Kato1, Katsuhito Yoshioka1, Akihiko Takeuchi1, Kazuya Shinmura1, Noriaki Yokogawa1, Takaki Shimizu1, Norihiro Oku1, Ryo Kitagawa1, Makoto Handa1, Hiroyuki Tsuchiya1.   

Abstract

OBJECTIVE: To evaluate the quantitative, radiologic, morphologic, and histologic effects of neoadjuvant denosumab treatment (DT) on 4 patients with spinal giant cell tumor of bone (GCTB) and determine the tumor shrinkage effects of DT for spinal GCTB.
METHODS: The morphologic changes in the 4 patients with spinal GCTB who underwent total spondylectomy after neoadjuvant DT at our institution were retrospectively analyzed using computed tomography. Osteolytic tumor volume, vertebral body height, maximum anterior and transverse diameter, and mean area of the spinal canal occupied by the tumor were evaluated.
RESULTS: In all patients, osteolytic tumor volume decreased by 81.2% and vertebral body height decreased by 87.4% on average following DT. In 3 of 4 patients with osteolytic lesions and a thin cortical rim, vertebral collapse had progressed after DT. Conversely, vertebral collapse was not observed in one patient with adequate anterior cortical bone. Two patients showed a mean decrease of 96.7% in the maximum transverse diameter, whereas 2 had a mean increase of 109% due to vertebral collapse. The mean area of the spinal canal occupied by the tumor reduced from 56.1% to 15.1%.
CONCLUSIONS: In all patients, osteolytic tumor volume decreased after DT. This tumor shrinkage effect of DT may increase the mechanical stress on the thin cortical rim, leading to the acute collapse of the affected vertebral body if it consists mostly of osteolytic lesions. The presence of adequate anterior cortical bone could prevent acute vertebral collapse after DT.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Collapse; Denosumab; Giant cell tumor; RANKL; Shrinkage; Spine; Spondylectomy

Mesh:

Substances:

Year:  2019        PMID: 30926552     DOI: 10.1016/j.wneu.2019.03.185

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  4 in total

1.  Giant cell tumor of bones- An unsolved puzzle.

Authors:  Akshay Tiwari; Raju Vaishya
Journal:  J Clin Orthop Trauma       Date:  2019-10-01

2.  Radiologic and clinical changes after denosumab treatment for giant cell tumors of the mobile spine: a quantitative study.

Authors:  Bei Yuan; Songbo Han; Shaomin Yang; Lihua Zhang; Liang Jiang; Feng Wei; Huishu Yuan; Xiaoguang Liu; Zhongjun Liu
Journal:  Insights Imaging       Date:  2022-05-26

Review 3.  Diagnosis and Treatment of Lumbar Giant Cell Tumor of the Spine: Update on Current Management Strategies.

Authors:  Andrew R Leggett; Ari R Berg; Heidi Hullinger; Joseph B Benevenia
Journal:  Diagnostics (Basel)       Date:  2022-03-30

Review 4.  State of the Art and New Concepts in Giant Cell Tumor of Bone: Imaging Features and Tumor Characteristics.

Authors:  Anna Parmeggiani; Marco Miceli; Costantino Errani; Giancarlo Facchini
Journal:  Cancers (Basel)       Date:  2021-12-15       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.